Connect with us

BUSINESS

Betterlife Pharma Inc. (OTCMKTS: BETRF) Receives First Data Set for Its Flagships LSD-Derivative Compound In Depression Treatment

Published

on

Betterlife Pharma Inc. (OTCMKTS: BETRF) has announced receipt of the first neurological receptor functional binding data set in its flagship compound, 2-Bromo-LSD (TD-0148A)

TD-0148A is a second-generation LSD derivative 

The company thinks that TD-0148A, a second-generation Lysergic Acid Diethylamide (“LSD”) derivative compound, will imitate the expected therapeutic potential of LSD without the psychoactive dissociative side effects like hallucinations. According to the receptor binding data, TD-0148A has distinct functional activity (agonism, neural, or antagonism) on neurological receptors that are known to play a role in neuropsychiatric diseases. In addition, the 5-hydroxytryptamine (serotonin) (5-HT) receptor family was of special interest, as TD-0148A showed varied functional activity with specific 5HT receptor subtypes.

BetterLife CEO  Dr. Ahmad Doroudian said, “We are pleased to confirm the differential activity of BetterLife TD-0148A on key neurotransmitter receptors. These results will provide the basis for ongoing preclinical pharmacology studies to understand the basis of the difference between TD-0148A and its parent compound, LSD, in particular the lack of hallucinations with TD-0148A.”

“TD-0148A is protected by several BetterLife-owned patents (granted and provisional). BetterLife believes that TD-0148A has great therapeutic potential for the treatment of debilitating psychiatric and neurological disorders with high unmet need, such as depression, post-traumatic stress disorder and cluster headaches. It is towards this goal that we are putting all our resources and hope to bring TD-0148A to US IND and the clinic by H2 2022,” added Dr. Doroudian.

Depression medicine market to hut $25 billion by 2030

TD-0148A is currently in IND-enabling and preclinical studies, and the company is developing this non-controlled and non-hallucinogenic LSD compound as a self-administered drug for neurological and neuropsychiatric disorders. The company’s TD-0148A synthesis patent removes regulatory barriers. Its pending composition and method-of-use patent cover the treatment of depression, post-traumatic stress disorder, cluster headaches, and other neurological and neuropsychiatric illnesses. In 2019, the global depression medicine market was worth $12.41 billion, with a forecast of reaching over $25 billion by 2030. According to the World Health Organization, depression is one of the most common causes of disability, affecting around 265 million people worldwide.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Revive Therapeutics Inc. (OTCMKTS: RVVTF) Signs Psilocybin Research Partnership Agreement With PharmaTher Holdings Ltd. (OTCMKTS: PHRRF)

Published

on

Revive Therapeutics Inc. (OTCMKTS: RVVTF) has signed a research partnership agreement with clinical psychedelics biotechnology firm PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate psilocybin delivery using PharmaTher’s patented microneedle patch tech for neuropsychiatric disorders.

Revive Therapeutics partners with Pharmather 

Revive Therapeutics CEO, Michael Frank, commented, “Our focus is developing and commercializing a specialty psilocybin-based product portfolio, and the research collaboration with PharmaTher complements our psilocybin product offerings as potential treatments for mental illness, substance abuse and neurological disorders. We believe there is no one-fits-all product profile solution with psilocybin. For psilocybin to be a next-generation therapeutic, different use and delivery forms will be required to achieve the intended target indications. As such, we aim to become a leader in psilocybin-based solutions for unmet medical needs by collaborating with companies that have intellectual property and experience in their delivery technologies, such as PharamTher.”

To support an IND submission with the FDA for clinical trials in 2022, PharmaTher is now performing IND-enabling research investigations with MicoDose-MN, a patent-pending biodegradable and biocompatible gelatin methacryloyl microneedle patch to deliver psilocybin. The psilocybin research results with MicroDose-MN will be available in November 2021.

The company is also testing its MacroDose-MN and MicroDose-MN patch as a next-generation psychedelics delivery method for ketamine, LSD, 3,4-methylenedioxymethamphetamine (“MDMA”), and N, N-dimethyltryptamine (“DMT”) in research studies.  The MacroDoes-MN and MicroDose-MN patches can potentially penetrate the stratum corneum layer and allow flexible drug load capacity. In addition, the company has opted to incorporate ibogaine and mescaline in its studies.

Microneedle is a next-gen psychedelics delivery system 

PharmaTher CEO Fabio Chianelli said, “We are pleased to collaborate with Revive in achieving their product portfolio objectives with psilocybin. Our microneedle patch technologies aim to become a next generation delivery system for psychedelics for various indications and healthcare environments. Although our focus remains on building our ketamine-based product pipeline, we will continue to partner with specialty pharmaceutical companies seeking a delivery solution for psychedelics and proprietary drugs to unlock significant value and return on investment for PharmaTher.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) And BRNT Ltd Enter Definitive Agreement On Leading Pre-Roll, Violet Tourist

Published

on

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) has entered a definitive white label agreement with Alberta-headquartered cannabis ancillary and brand house operator, BRNT Ltd which launched leading dried cannabis flower and pre-roll, Violet Tourist.

Violet Tourist has generated wholesale revenue of $2.5 million.

The companies will partner to introduce Violet Tourist branded cannabis 2.0 infused pre-rolls across  Alberta soon as per the agreement terms. Heritage will attempt to extend the brand’s distribution across Canada and add to its growing SKU listings in the cannabis 1.0 and 2.0 categories throughout the agreement. The arrangement terms give Heritage rights over the supply chain and procurement, thereby granting it complete ownership of the well-known Alberta brand. Since its launch, Violet Tourists has generated wholesale revenue of $2.5 million.

CEO of BRNT, Gage Gorda, said, “During 2020, BRNT commenced with a process to identify a new partner for our Violet Tourist branded products. We had serious inquiries from numerous LP’s in the Country, including some of the largest, but none came close to the product offering capabilities, speed to market, depth of relationships with provincial buyers and most of all internal culture and leadership than Heritage.”

Heritage and BRNT to partner on RAD and Pura Vida Hexagonal bong

Heritage and BRNT are also looking to form a business partnership to release a RAD and Pura Vida-branded Hexagon bong available to customers in both Canada and the US. The patent-protected ceramic Hexagon bong by BRNT was recently named one of Rolling Stone magazine’s Best Bongs of 2021.

David Schwede, Heritage CEO, said, “We are thrilled to have executed this Agreement with BRNT as it provides us with control of a brand in Alberta that has proven its ability to capture market in Canada’s second largest market by revenue. Without a cash outlay or issuance of Heritage shares, we secure exclusive cannabis 2.0 rights to Violet Tourist branded products in Alberta and retain control to expand distribution of the brand across the Country and into cannabis 1.0 formats over the duration of the Agreement.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) Reports Record Fourth Quarter Sales and Signs Definitive Agreement with BRNT

Published

on

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) has announced a third record gross revenue quarter running, and the company anticipates increases of 20-25% QoQ attributable to the strong sales growth witnessed throughout Q4.

Heritage focuses on sales growth and cost reduction 

The company has been focusing on cost reduction across its operations in addition to sales and revenue growth, and on current trends, it expects to be cash-flow positive in early calendar 2022.

Heritage’s sales compound annual growth rate from February 2021 to August 2021 was over 16 percent, compared to the average CAGR of 3% for the top eight Canadian Licensed Producers, according to data just released by Headset. In addition, over the most recent three-month period at the time, Heritage had a 19% growth in sales, compared to a 3% loss for the same group.

Heritage CEO David Schwede said, “Heritage has continued to outpace our larger peers in sales growth, and we don’t plan on slowing down. The growth in sales and prudent cost management we have undertaken in the past few months are driving the Company towards positive cash flow as early as the beginning of calendar 2022. Our portfolio expansion of 34 skus in the flower and preroll categories, the largest segments of the market, will see results start to take shape in the coming quarters. Building a strong, self sufficient and sustainable business does not occur without strong business practices, and I am excited to see that we are within striking distance of accomplishing this in the cannabis sector.”

Heritage enters definitive label agreement with BRNT

Recently the company entered a definitive white label agreement with BRNT Ltd, which is the cannabis firm that launched dried flower and pre-roll brand, Violet Tourist. Under the agreement, Heritage plans to collaborate with BRNT to launch Violet Tourist cannabis 2.0 infused pre-roll I Alberta. The agreement terms offer the company procurement and supply chain controls and effectively give Heritage rights to operate the brand. The companies are also exploring a commercial deal to launch Pura Vida, and RAD branded Hexagon bong.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories